Investor Presentation H1 2023
9
Investor presentation
First six months of 2023
Novo NordiskⓇ
Obesity care sales grew by 157% in the first half of 2023 mainly
driven by the US
NN sales and volume BAOM market growth
within Obesity care
Branded AOM TRX in the US²
DKK billion
12
55%¹
TRX count ('000s)
84%1
157%1
180
76%
75%
160
140
124
•
8
55%
120
94
100
35%
80
60
4
40
15%
20
0
0
-5%
2021
2022
2023
June
2021
IO
INAO
- BAOM Market growth (RHS)
SaxendaⓇ
20
Norway and Germany
Limited roll-out in IO in 2023
July
2023
balancing supply and demand
-WegovyⓇ
•
ONCE-WEEKLY
wegovy
semaglutide injection 2.4 mg
The US
Commercial relaunch in January 2023
Broad commercial formulary access
While supply capacity is gradually
being expanded, the supply of the
lower dose strengths will remain
restricted to safeguard continuity of
care
International Operations
WegovyⓇ launched in Denmark,
INN sales growth at CER
Branded AOM market
1Annual growth at CER. Each TRX data points represents one week of data; 2IQVIA weekly, 28 July 2023
NAO: North America operations; IO: International operations; RHS: Right-hand side axis; Rx: Prescriptions; AOM: Anti-Obesity Medications (includes Wegovy®, SaxendaⓇ, Qsymia, Belviq and Contrave); CER: Constant exchange rates
Note: Sales growth at constant exchange rates. 76% volume growth for Global BAOM market growth refers to moving annual total.View entire presentation